Search the Newsreel

Real Brokerage (NASDAQ:REAX) Given New $4.00 Price Target at Edward Jones

Edward Jones has lowered its price target for Real Brokerage (NASDAQ:REAX) from $5.00 to $4.00, but maintained a "buy" rating, indicating a potential upside of 101.01%. Despite a quarterly loss of $0.03 per share, the company holds a consensus "Moderate Buy" rating among analysts …

Real’s revenue jumps 30% with REMAX deal pending

The Real Brokerage announced a 30% year-over-year revenue increase to $700.6 million in Q2 2026, despite a slow housing market. This growth comes ahead of a planned securityholder vote on Real's acquisition of REMAX, with CEO Tamir Poleg expressing optimism about the merger. The …

The Real Brokerage Reports Q2 2026 Financial Results

The Real Brokerage Inc. announced its Q2 2026 financial results, reporting a 30% year-over-year revenue growth to $700.6 million and a net loss of $8 million. The company is proceeding with its acquisition of REMAX, expecting to close in the second half of 2026, …

SunCoke Energy Inc (SXC) News, Articles, Events & Latest Updates

Earnings call transcript: Real Brokerage tops revenue estimates in Q2 2026

Real Brokerage Technologies reported stronger-than-expected revenue of $700.6 million in Q2 2026, surpassing analyst estimates, driven by record transaction volume and market-share gains. Despite this, the company posted an adjusted loss of 3 cents per share, missing the 1-cent profit expectation, largely due to …

Real Brokerage posts 30% revenue growth as Remax vote nears

The Real Brokerage Inc. reported significant second-quarter results with revenue growing 30% to US$700.6 million and adjusted EBITDA up 38% to $27.6 million, despite a net loss primarily due to acquisition costs for Remax. The company is making progress on its $880 million acquisition …

Interactive Brokers Group (IBKR) After Shelf Filing Is The Stock A Bargain Or Priced In

Interactive Brokers Group (IBKR) has filed a shelf registration, providing flexibility for future stock issuance, which comes after a recent dip in share price but strong year-to-date and one-year returns. The article discusses two contrasting valuation views: one narrative suggesting IBKR is 18% undervalued …

FMR LLC discloses 8.5% Stoke Therapeutics (STOK) ownership in Schedule 13G/A

FMR LLC has filed an amended Schedule 13G/A, reporting a passive ownership stake of 8.5% in Stoke Therapeutics (STOK) common stock. This represents 5,313,100 shares, with FMR LLC holding sole voting power over 5,312,516 shares and sole dispositive power over all 5,313,100 shares. Abigail …

Smart Money Move: J. Lindsey Alley Grabs $500K Worth Of Houlihan Lokey Stock

The Real Brokerage Inc. (REAX) Reports Q2 Loss, Tops Revenue Estimates

The Real Brokerage Inc. (REAX) reported a Q2 loss of $0.03 per share, missing the Zacks Consensus Estimate of a $0.01 loss. However, the company surpassed revenue estimates, posting $700.58 million against an estimate of $656.49 million. Despite beating revenue expectations for four consecutive …

Are Investors Undervaluing SunCoke Energy (SXC) Right Now?

Zacks Equity Research suggests that SunCoke Energy (SXC) appears to be undervalued, currently holding a Zacks Rank #2 (Buy) and a Value grade of A. The article highlights various valuation metrics such as P/E, P/B, P/S, and P/CF ratios, all of which indicate that …

Is Okeanis Eco Tankers Corp. (ECO) Stock Outpacing Its Transportation Peers This Year?

For those looking to find strong Transportation stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Okeanis Eco Tankers Corp. (ECO) been one of those stocks this year? Let's take a closer look at the stock's …

The Real Brokerage’s (NASDAQ:REAX) Q2 CY2026 Sales Top Estimates

The Real Brokerage (NASDAQ:REAX) reported better-than-expected revenue in Q2 CY2026, with sales reaching $700.6 million, a 29.6% increase year-on-year, surpassing analyst estimates. Despite missing GAAP EPS estimates with a loss of $0.03 per share, the company's adjusted EBITDA beat expectations. The article highlights the …

Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report

Stoke Therapeutics (NASDAQ:STOK) saw its shares rise 8.3% after its second-quarter report, with revenues of US$9.3m exceeding expectations, though losses also increased. Analysts have since raised revenue estimates for 2026 to US$30.2m but also increased loss per share forecasts to US$3.71, indicating higher costs …

[6-K] Real Brokerage Inc Current Report (Foreign Issuer)

Real Brokerage Inc. filed a Form 6-K report detailing the ongoing merger with RE/MAX Holdings, Inc., which is expected to close in the second half of 2026, pending securityholder and shareholder approval. The filing provides supplemental information regarding the proposed acquisition, including J.P. Morgan's …

Real Brokerage keeps growth streak alive as REMAX deal nears

The Real Brokerage reported robust Q2 2026 results, with revenue up 30% to $700.6 million and adjusted EBITDA rising 38% to $27.6 million, despite a net loss primarily due to acquisition costs for the pending REMAX deal. Agent count increased significantly, driving a 31% …

CX Institutional Trims Position in ONEOK, Inc. $OKE

CX Institutional significantly reduced its stake in ONEOK, Inc. by 68.5% in the second quarter, selling over 44,000 shares. Despite this, ONEOK reported strong Q2 earnings, beating estimates for EPS and revenue, and raised its 2026 outlook. The company also declared a quarterly dividend …

The Real Brokerage Inc. (REAX) News, Articles, Events & Latest Updates

This article provides recent news and updates for The Real Brokerage Inc. (REAX), highlighting their Q2 2026 financial results which reported a loss but topped revenue estimates. It also details the expansion of the company through new team acquisitions, the upcoming merger with RE/MAX, …

Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates

Real Brokerage (REAX) Earnings Date and Reports 2026

All You Need to Know About Okeanis Eco Tankers Corp. (ECO) Rating Upgrade to Strong Buy

Does Houlihan Lokey (HLI) Prioritize Capital Returns Over Earnings Momentum With Its Latest Results?

Houlihan Lokey reported softer first-quarter 2026 earnings but maintained its leading position in M&A deal count and continued significant capital returns through dividends and share repurchases. The company's investment narrative now focuses on its ability to convert deal volume into resilient earnings despite cost …

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Stoke Therapeutics announced that its CEO, Ian F. Smith, and Chief Patient Officer, Jason Hoitt, will present at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The biotechnology company focuses on RNA medicine to restore protein expression, with its lead investigational …

Stoke Therapeutics (NASDAQ:STOK) Insider Sells $208,391.04 in Stock

Stoke Therapeutics insider Barry Ticho sold 7,176 shares of the company's stock for $208,391.04, reducing his holdings by 26%. This sale was made under a Rule 10b5-1 trading plan. The company recently reported mixed quarterly results, with revenue exceeding estimates but a wider-than-expected loss, …

Stoke Therapeutics (STOK) CMO sells 7,176 shares under 10b5-1 plan

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 7,176 shares of common stock on August 3, 2026, under a Rule 10b5-1 trading plan adopted on November 19, 2025. The sales occurred in two transactions at weighted-average prices of $28.9501 and $29.4539 per share. Following …

ONEOK Releases Annual Corporate Sustainability Report

ONEOK, Inc. announced the release of its annual Corporate Sustainability Report, which is now available on the company's website. ONEOK is a leading midstream operator headquartered in Tulsa, Oklahoma, providing essential energy products and services through its extensive pipeline network across North America. The …

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics reported its Q2 2026 financial results, highlighting significant progress in its clinical programs. The company completed enrollment for the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with data expected in Q3 2027, and plans to initiate a rolling U.S. NDA …

ONEOK's 60,000-Mile Network Moves Gas, Oil and NGLs for Energy Demand

ONEOK (NYSE: OKE) has released its annual Corporate Sustainability Report, detailing its role as a leading midstream operator with an extensive 60,000-mile pipeline network. The report emphasizes the company's commitment to providing safe, reliable, and responsible energy solutions by transporting natural gas, NGLs, refined …

Need To Know: Analysts Are Much More Bullish On ONEOK, Inc. (NYSE:OKE) Revenues

Analysts have significantly increased their revenue forecasts for ONEOK, Inc. (NYSE:OKE), with the consensus estimate for 2026 rising by 12% to US$22 billion. This optimistic outlook comes despite the company's shares experiencing a 7.5% drop over the last month, suggesting a potential disconnect between …

Stoke: 'Buy' Zorevunersen NDA SCN1A DS And STK-002 Advancement (NASDAQ:STOK)

Stoke Therapeutics (STOK) maintains a "Buy" rating due to significant progress in its clinical programs. Key milestones include an expected FDA meeting in H2 2026 and a rolling NDA submission in Q1 2027 for zorevunersen in SCN1A Dravet Syndrome, with Phase 3 EMPEROR data …

Freedom Capital Markets Upgrades ONEOK Inc(OKE.US) to Buy Rating, Raises Target Price to $105

Freedom Capital Markets has upgraded its rating for ONEOK Inc (OKE.US) from "Hold" to "Buy." Concurrently, the firm increased its price target for the company's shares to $105. This upgrade reflects a more optimistic outlook on ONEOK's future performance.

Earnings call transcript: Okeanis Eco Tankers posts record Q2 2026 beat

Key Points Interested in Okeanis Eco Tankers Corp.? Here are five stocks we like better. Record results: Okeanis Eco Tankers reported adjusted EPS of $5.91 in Q2 2026 and $8.28 for the first half, alongside quarterly adjusted EBITDA of $252 million. The board declared …

Freedom Broker upgrades ONEOK stock rating on strong Q2 results

Freedom Broker upgraded ONEOK Inc. (NYSE:OKE) from Hold to Buy, increasing its price target to $105 from $102, citing the stock's undervaluation and strong Q2 2026 results. The energy infrastructure company exceeded revenue and adjusted EPS expectations due to volume growth and has a …

OKE Q2 Earnings Call Highlights Higher Guidance and Project Growth

ONEOK, Inc. (OKE) raised its 2026 financial guidance following strong Q2 results, with adjusted EBITDA midpoint increased by $250 million. The company's management detailed significant project developments, including pipeline expansions and plant up-sizes, contributing to a positive long-term growth outlook. Despite some NGL margin …

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange

GREENWICH, Conn., August 05, 2026--(BUSINESS WIRE)--Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors …

Oneok (OKE) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2026, Oneok Inc. (OKE) reported revenue of $12.05 billion, up 52.8% over the same period last year. EPS came in at $1.53, compared to $1.34 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of …